View ValuationSynBiotic 향후 성장Future 기준 점검 5/6SynBiotic (는) 각각 연간 72.4% 및 27.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 76.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -4.9% 로 예상됩니다.핵심 정보72.4%이익 성장률76.09%EPS 성장률Pharmaceuticals 이익 성장23.9%매출 성장률27.2%향후 자기자본이익률-4.90%애널리스트 커버리지Low마지막 업데이트19 Dec 2025최근 향후 성장 업데이트Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.Breakeven Date Change • Apr 27Forecast to breakeven in 2023The 2 analysts covering SynBiotic expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 61% to 2022. The company is expected to make a profit of €300.0k in 2023. Average annual earnings growth of 123% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Mar 18SynBiotic SE, Annual General Meeting, Apr 23, 2026SynBiotic SE, Annual General Meeting, Apr 23, 2026, at 10:00 W. Europe Standard Time.공시 • Apr 19SynBiotic SE announced that it expects to receive €2.4 million in fundingSynBiotic SE announced a private placement that it will issue non-interest-bearing convertible bonds for the gross proceeds of up to €2,400,000 on April 17, 2025. The company will issue in several tranches of up to €200,000 each. The issue of the first convertible bonds is scheduled to start at the end of April 2025.New Risk • Aug 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.9m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Revenue is less than US$5m (€4.1m revenue, or US$4.5m). Market cap is less than US$100m (€31.6m market cap, or US$35.1m).공시 • Aug 15SynBiotic SE, Annual General Meeting, Sep 20, 2024SynBiotic SE, Annual General Meeting, Sep 20, 2024, at 10:00 W. Europe Standard Time.New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (€37.7m market cap, or US$40.4m).New Risk • Jun 21New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€35.6m market cap, or US$38.0m).New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (25% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€400k net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€35.8m market cap, or US$39.2m).New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€400k net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€14.0m market cap, or US$15.3m).Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.Breakeven Date Change • Apr 27Forecast to breakeven in 2023The 2 analysts covering SynBiotic expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 61% to 2022. The company is expected to make a profit of €300.0k in 2023. Average annual earnings growth of 123% is required to achieve expected profit on schedule.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.이익 및 매출 성장 예측DB:SBX - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202724N/A00212/31/202619-1-10212/31/202516-2-1-1212/31/202416-2-3-3212/31/20234-11-3-3N/A12/31/20228-24-7-7N/A12/31/20219-13-6-5N/A12/31/20205-1-3-1N/A12/31/2019N/A000N/A애널리스트 향후 성장 전망수입 대 저축률: SBX 의 연간 예상 수익 증가율(72.4%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: SBX 의 연간 수익(72.4%)이 German 시장(17%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: SBX 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: SBX 의 수익(연간 27.2%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: SBX 의 수익(연간 27.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SBX는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 20:00종가2026/05/21 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SynBiotic SE는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Harald Hofmwb research AGChristian SandherrNuWays AG
Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.
Breakeven Date Change • Apr 27Forecast to breakeven in 2023The 2 analysts covering SynBiotic expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 61% to 2022. The company is expected to make a profit of €300.0k in 2023. Average annual earnings growth of 123% is required to achieve expected profit on schedule.
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Mar 18SynBiotic SE, Annual General Meeting, Apr 23, 2026SynBiotic SE, Annual General Meeting, Apr 23, 2026, at 10:00 W. Europe Standard Time.
공시 • Apr 19SynBiotic SE announced that it expects to receive €2.4 million in fundingSynBiotic SE announced a private placement that it will issue non-interest-bearing convertible bonds for the gross proceeds of up to €2,400,000 on April 17, 2025. The company will issue in several tranches of up to €200,000 each. The issue of the first convertible bonds is scheduled to start at the end of April 2025.
New Risk • Aug 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.9m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Revenue is less than US$5m (€4.1m revenue, or US$4.5m). Market cap is less than US$100m (€31.6m market cap, or US$35.1m).
공시 • Aug 15SynBiotic SE, Annual General Meeting, Sep 20, 2024SynBiotic SE, Annual General Meeting, Sep 20, 2024, at 10:00 W. Europe Standard Time.
New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (€37.7m market cap, or US$40.4m).
New Risk • Jun 21New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€35.6m market cap, or US$38.0m).
New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (25% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€400k net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€35.8m market cap, or US$39.2m).
New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€400k net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€14.0m market cap, or US$15.3m).
Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.
Breakeven Date Change • Apr 27Forecast to breakeven in 2023The 2 analysts covering SynBiotic expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 61% to 2022. The company is expected to make a profit of €300.0k in 2023. Average annual earnings growth of 123% is required to achieve expected profit on schedule.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.